Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial

McGarry, Andrew; Rosanbalm, Shane; Leinonen, Mika; Olanow, C Warren; To, Dennis; Bell, Adam; Lee, Daniel; Chang, Jamie; Dubow, Jordan; Dhall, Rohit; Burdick, Daniel; Parashos, Sotirios; Feuerstein, Jeanne; Quinn, Joseph; Pahwa, Rajesh; Afshari, Mitra; Ramirez-Zamora, Aldolfo; Chou, Kelvin; Tarakad, Arjun; Luca, Corneliu; Klos, Kevin; Bordelon, Yvette; St Hiliare, Marie-Helene; Shprecher, David; Lee, Seulki; Dawson, Ted M; Roschke, Viktor; Kieburtz, Karl

doi:10.1016/s1474-4422(23)00378-2

Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial

BACKGROUND Converging lines of evidence suggest that microglia are relevant to Parkinson's disease pathogenesis, justifying exploration of therapeutic agents thought to attenuate pathogenic microglial function. We sought to test the safety and efficacy of NLY01-a brain-penetrant, pegylated, longe…